ITCI

Intra-Cellular Therapies (ITCI) is the lead sponsor of 14 active clinical trials listed on ClinicalTrials.gov^[4], including 7 Phase 3^[1], 5 Phase 2^[2], 2 Phase 1^[3].

Trial NCT05850689^[5] evaluates Lumateperone in Major Depressive Disorder with a target enrollment of 470 participants. Trial NCT06229210^[6] evaluates Lumateperone in Schizophrenia with a target enrollment of 500 participants. Trial NCT06706674^[7] evaluates Lumateperone high dose in Irritability Associated With Autism Spectrum Disorder with a target enrollment of 174 participants.

No Form 4 insider filings for ITCI were recorded at the SEC in the past 30 days^[8].